Loading...
Market
How many Walgreens sites will successfully enroll participants in the BARDA Project NextGen study by December 31, 2024?
3
Resolution / Starting Odds
0-5 sites • 25%
6-10 sites • 25%
11-15 sites • 25%
16-20 sites • 25%
Official announcement from Walgreens or HHS
Story
HHS Announces Walgreens' BARDA Award for COVID-19 Decentralized Clinical Study Under Project NextGen
Jul 23, 2024, 01:01 PM
Walgreens has received the BARDA Project NextGen Award to conduct a novel COVID-19 decentralized clinical study. The study, which is part of a Phase IV trial, will be carried out in partnership with the RRPV Consortium and will focus on a US FDA authorized or approved COVID-19 vaccine. The trial aims to identify correlates of protection for COVID vaccines and will take place at approximately 20 Walgreens sites, ranging from urban to rural locations. HHS announces the pharmacy-based clinical trial under Project NextGen.
View original story
Similar markets
Less than 50 • 25%
50 to 100 • 25%
101 to 200 • 25%
More than 200 • 25%
0-10 • 25%
11-20 • 25%
21-30 • 25%
31 or more • 25%
Less than 5,000 • 25%
5,000 to 10,000 • 25%
10,001 to 20,000 • 25%
More than 20,000 • 25%
Yes • 50%
No • 50%
Less than 50 • 25%
50 to 100 • 25%
101 to 200 • 25%
More than 200 • 25%
Less than 200 • 25%
200 to 400 • 25%
401 to 600 • 25%
More than 600 • 25%
Less than 400 • 25%
400 to 500 • 25%
501 to 600 • 25%
More than 600 • 25%
1-2 • 25%
3-4 • 25%
5-6 • 25%
7 or more • 25%
Less than 400 • 25%
400 to 499 • 25%
500 to 599 • 25%
600 or more • 25%
Yes • 50%
No • 50%